Nicolas Novitzky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Nicolas Novitzky has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Herman Waldmann
Sir William Dunn School of Pathology, Oxford, United Kingdom
2 shared publications A. McDonald
The University of Cape Town Leukaemia Centre and the Department of Haematology Groote Schuur Hospital, Observatory, Cape Town, South Africa
1 shared publicationAndrew McDonald
Department of Haematology, Groote Schuur Hospital (GSH), University of Cape Town, Cape Town, South Africa
1 shared publicationC. du Toit
The University of Cape Town Leukaemia Centre and the Department of Haematology Groote Schuur Hospital, Observatory, Cape Town, South Africa
1 shared publicationCécile Du Toit
Department of Haematology, Groote Schuur Hospital (GSH), University of Cape Town, Cape Town, South Africa
1 shared publicationG Hale
The Dunn School of Pathology, Oxford University, Oxford, UK
1 shared publication
Latest Publications
- 1 January 2007
- Vol. 13 (1) , 107-15
Allogeneic stem cell transplantation with T cell-depleted grafts for lymphoproliferative malignancies.
In non-Hodgkin lymphoma allogeneic stem cell transplantation (SCT) can be curative, but with standard dose conditioning patients may have substantial morbidity and mortality from graft-versus-host disease (GVHD); for aggressive malignancies, reduced intensity conditioning may result in higher recurrence. Patients with advanced follicular lymphoma (n = 12), transformed B cell malignancy (n = 11), and non-CD30+T cell lymphomas (n = 17) responsive to chemotherapy who had an HLA-identical sibling were offered T cell depleted (CAMPATH-1 G or H antibodies) SCT. Conditioning was with ablative doses of chemotherapy or radiotherapy. Before SCT, patients with follicular lymphoma had a median of 3 treatment courses, and those with transformed B cell and those diagnosed with T cell non-Hodgkin lymphoma had 2 (range, 1-3). At SCT the median age was 46 years (range, 21-59 years) and the number of CD34+ cells infused was 2.85 x 10(6)/kg. All patients showed engraftment but 7 patients (17.5%) developed GVHD. In total 12 subjects expired of transplant-related causes (n = 6) or from disease recurrence. One-year transplant-related mortality was 15%. There was no difference in survival across diagnostic groups. At a median of 1051 days, 70% survived and 68% are without disease. By reducing the incidence and severity of GVHD, patients can tolerate myeloablative doses of chemotherapy satisfactorily. This has resulted in low treatment-related mortality and adequate protection from disease recurrence.
- 1 January 2007
- Vol. 13 (1) , 107-15
Allogeneic stem cell transplantation with T cell-depleted grafts for lymphoproliferative malignancies.
In non-Hodgkin lymphoma allogeneic stem cell transplantation (SCT) can be curative, but with standard dose conditioning patients may have substantial morbidity and mortality from graft-versus-host disease (GVHD); for aggressive malignancies, reduced intensity conditioning may result in higher recurrence. Patients with advanced follicular lymphoma (n = 12), transformed B cell malignancy (n = 11), and non-CD30+T cell lymphomas (n = 17) responsive to chemotherapy who had an HLA-identical sibling were offered T cell depleted (CAMPATH-1 G or H antibodies) SCT. Conditioning was with ablative doses of chemotherapy or radiotherapy. Before SCT, patients with follicular lymphoma had a median of 3 treatment courses, and those with transformed B cell and those diagnosed with T cell non-Hodgkin lymphoma had 2 (range, 1-3). At SCT the median age was 46 years (range, 21-59 years) and the number of CD34+ cells infused was 2.85 x 10(6)/kg. All patients showed engraftment but 7 patients (17.5%) developed GVHD. In total 12 subjects expired of transplant-related causes (n = 6) or from disease recurrence. One-year transplant-related mortality was 15%. There was no difference in survival across diagnostic groups. At a median of 1051 days, 70% survived and 68% are without disease. By reducing the incidence and severity of GVHD, patients can tolerate myeloablative doses of chemotherapy satisfactorily. This has resulted in low treatment-related mortality and adequate protection from disease recurrence.
- Open Access
- 22 August 2005
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 36 (8) , 675-682
Myeloablative conditioning is well tolerated by older patients receiving T-cell-depleted grafts
Older age has been linked to increased transplant-related mortality from graft-versus-host disease (GvHD). Depletion of T cells from stem cell grafts seems to protect from complications of GvHD particularly in older patients. After myeloablative conditioning, patients with haematological malignancies received allogeneic grafts from HLA identical siblings. For GvHD prophylaxis, PBPC grafts were treated ex vivo with anti-CD52, and therapeutic doses of cyclosporin until day +90. Survival of patients younger or older than the population age median was analysed. In all, 62 consecutive patients with a median age of 42.5 years were studied. Death was procedure related in 17% and from relapse of malignancy in five. At a median, follow-up is 662 (7–2316) days, 74% survive disease free. The rate of haematopoietic recovery and treatment-related mortality was similar in both groups. A total of 73% of 30 individuals in the younger group and 75% (P=0.8) in the older cohort survive at a median follow-up of 444 and 806 days (P=0.4). GvHD occurred in 13% and was the only adverse factor for survival (P<0.04). Myeloablative conditioning is well tolerated up to the age of 59 in patients receiving T-cell-depleted grafts. This information is useful to more precisely select patients who would benefit most from reduced intensity conditioning schedules.
- 22 August 2005
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 36 (8) , 675-682
Open AccessMyeloablative conditioning is well tolerated by older patients receiving T-cell-depleted grafts
Older age has been linked to increased transplant-related mortality from graft-versus-host disease (GvHD). Depletion of T cells from stem cell grafts seems to protect from complications of GvHD particularly in older patients. After myeloablative conditioning, patients with haematological malignancies received allogeneic grafts from HLA identical siblings. For GvHD prophylaxis, PBPC grafts were treated ex vivo with anti-CD52, and therapeutic doses of cyclosporin until day +90. Survival of patients younger or older than the population age median was analysed. In all, 62 consecutive patients with a median age of 42.5 years were studied. Death was procedure related in 17% and from relapse of malignancy in five. At a median, follow-up is 662 (7–2316) days, 74% survive disease free. The rate of haematopoietic recovery and treatment-related mortality was similar in both groups. A total of 73% of 30 individuals in the younger group and 75% (P=0.8) in the older cohort survive at a median follow-up of 444 and 806 days (P=0.4). GvHD occurred in 13% and was the only adverse factor for survival (P<0.04). Myeloablative conditioning is well tolerated up to the age of 59 in patients receiving T-cell-depleted grafts. This information is useful to more precisely select patients who would benefit most from reduced intensity conditioning schedules.
- 24 January 2005
- Published by Wiley in British Journal of Haematology
- Vol. 128 (3) , 373-379
Thrombotic thrombocytopenic purpura in patients with retroviral infection is highly responsive to plasma infusion therapy
Summary: We prospectively studied presentation biological differences and the response to therapy in patients with thrombotic thrombocytopenic purpura (TTP) associated with, or unrelated to human immunodeficiency virus (HIV) infection. TTP patients underwent standard evaluations and were treated with prednisone 1 mg/kg in addition to infusions of fresh frozen plasma (FFP; 30 ml/kg/d) until normalization of the platelet count. Unresponsive patients were referred for plasma exchange. Compared with HIV− TTP patients (n = 23), in HIV+ subjects (n = 21) microangiopathy was dominant among Black females, who had lower presentation Hb (median 5·8 g/dl; P = 0·03), platelet count (13 × 109/l; P = 0·05) and a CD4 count of 0·096 × 109/l. HIV+ individuals responded to FFP faster than HIV− patients and none of them required apheresis. Ten HIV− TTP patients required apheresis (P = 0·03) and four died. Responses in the HIV+ and HIV− groups occurred after treatment with a median of 33 and 55 units (one unit = 320 ml) of FFP (P = 0·004) respectively. Response to this protocol was seen in 84% (95% response in HIV+ patients). Regression analysis showed that survival was associated with younger age (P = 0·001), rapid platelet (P = 0·001) and Hb (P = 0·0009) recovery, and fewer FFP units to normal lactate dehydrogenase levels (P = 0·006). We conclude that in HIV+ individuals, microangiopathy is highly responsive to plasma infusions. This observation is important particularly when apheresis is not available.
- 24 January 2005
- Published by Wiley in British Journal of Haematology
- Vol. 128 (3) , 373-379
Thrombotic thrombocytopenic purpura in patients with retroviral infection is highly responsive to plasma infusion therapy
Summary: We prospectively studied presentation biological differences and the response to therapy in patients with thrombotic thrombocytopenic purpura (TTP) associated with, or unrelated to human immunodeficiency virus (HIV) infection. TTP patients underwent standard evaluations and were treated with prednisone 1 mg/kg in addition to infusions of fresh frozen plasma (FFP; 30 ml/kg/d) until normalization of the platelet count. Unresponsive patients were referred for plasma exchange. Compared with HIV− TTP patients (n = 23), in HIV+ subjects (n = 21) microangiopathy was dominant among Black females, who had lower presentation Hb (median 5·8 g/dl; P = 0·03), platelet count (13 × 109/l; P = 0·05) and a CD4 count of 0·096 × 109/l. HIV+ individuals responded to FFP faster than HIV− patients and none of them required apheresis. Ten HIV− TTP patients required apheresis (P = 0·03) and four died. Responses in the HIV+ and HIV− groups occurred after treatment with a median of 33 and 55 units (one unit = 320 ml) of FFP (P = 0·004) respectively. Response to this protocol was seen in 84% (95% response in HIV+ patients). Regression analysis showed that survival was associated with younger age (P = 0·001), rapid platelet (P = 0·001) and Hb (P = 0·0009) recovery, and fewer FFP units to normal lactate dehydrogenase levels (P = 0·006). We conclude that in HIV+ individuals, microangiopathy is highly responsive to plasma infusions. This observation is important particularly when apheresis is not available.
- 23 July 2004
- Published by Wiley in American Journal of Hematology
- Vol. 76 (4) , 319-329
Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia
To understand the effect of dose concentration in the overall survival of AML, we conducted a study on the efficacy and toxicity of a drug combination where the dose of daunorubicin was intensified. For this analysis, the outcome of patients entered into two consecutive prospective trials was compared. Inclusion criteria in both arms were identical and consisted of primary AML in adults. Treatment protocol for Cape Town Regimen 4 (CTR‐IV) comprised of cytarabine infusion (100 mg/m2) and etoposide (100 mg/m2), injection daily for 7 days in combination with daunorubicin (45 mg/m2) on days 1, 2, and 3. Patients achieving remission were given two further courses of the same chemotherapy and received allogeneic or autologous transplantation. CTR‐V was a similar treatment program, except that daunorubicin was escalated on days 1, 2, and 3 to 75 mg/m2during induction and to 60 mg/m2during a single consolidation. Patients were also offered stem cell transplantation. Between 1990 and 1997, 78 patients (median age 33; range 13–67 years) fulfilled entry criteria and received CTR‐IV. From 1998 onwards, 35 patients (median age 36; range 15–66 years) were prospectively enlisted into the CTR‐V trial. The patient population in CTR‐V had fewer Caucasian individuals (P= 0.02) and had significantly lower presentation hemoglobin (P= 0.0002). Following initiation of induction chemotherapy, 40 patients failed to respond. Among these, 10 patients demised before day 28. Another 30 (25/69 CTR‐IV and 5/32 in CTR‐V groups;P= 0.01) had leukemia that was resistant to chemotherapy, and all died. Remission was achieved in 59% of patients treated with CTR‐IV and 77% of those receiving CTR‐V (P= 0.03). CR occurred with a single course in 64% versus 88% (P= 0.02), respectively. There were no differences in the toxicity profile between these two combinations. Disease recurred in 50% and 28% (P= 0.07) of patients. For the 113 individuals, median follow up is 254 (range 19–4,451) and 304 (12–1,702;P= 0.03) days. Survival is 23% and 40%, respectively, favoring patients treated with CTR‐V (log rank;P= 0.03). Cox regression analysis showed that treatment group (P< 0.001), FAB type, hemoglobin level, and platelet count were independent factors for response to chemotherapy. Older age and not undergoing myeloablative therapy were the only adverse factors for survival. We conclude that increase in the treatment dose of daunorubicin in patients with AML led to a higher remission rate, particularly with a single course of chemotherapy and had an equivalent toxicity profile. This therapeutic modification is also likely to result in substantial reduction in patient stay in hospital and in the overall expenditure. Am. J. Hematol. 76:319–329, 2004.
- 23 July 2004
- Published by Wiley in American Journal of Hematology
- Vol. 76 (4) , 319-329
Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia
To understand the effect of dose concentration in the overall survival of AML, we conducted a study on the efficacy and toxicity of a drug combination where the dose of daunorubicin was intensified. For this analysis, the outcome of patients entered into two consecutive prospective trials was compared. Inclusion criteria in both arms were identical and consisted of primary AML in adults. Treatment protocol for Cape Town Regimen 4 (CTR‐IV) comprised of cytarabine infusion (100 mg/m2) and etoposide (100 mg/m2), injection daily for 7 days in combination with daunorubicin (45 mg/m2) on days 1, 2, and 3. Patients achieving remission were given two further courses of the same chemotherapy and received allogeneic or autologous transplantation. CTR‐V was a similar treatment program, except that daunorubicin was escalated on days 1, 2, and 3 to 75 mg/m2during induction and to 60 mg/m2during a single consolidation. Patients were also offered stem cell transplantation. Between 1990 and 1997, 78 patients (median age 33; range 13–67 years) fulfilled entry criteria and received CTR‐IV. From 1998 onwards, 35 patients (median age 36; range 15–66 years) were prospectively enlisted into the CTR‐V trial. The patient population in CTR‐V had fewer Caucasian individuals (P= 0.02) and had significantly lower presentation hemoglobin (P= 0.0002). Following initiation of induction chemotherapy, 40 patients failed to respond. Among these, 10 patients demised before day 28. Another 30 (25/69 CTR‐IV and 5/32 in CTR‐V groups;P= 0.01) had leukemia that was resistant to chemotherapy, and all died. Remission was achieved in 59% of patients treated with CTR‐IV and 77% of those receiving CTR‐V (P= 0.03). CR occurred with a single course in 64% versus 88% (P= 0.02), respectively. There were no differences in the toxicity profile between these two combinations. Disease recurred in 50% and 28% (P= 0.07) of patients. For the 113 individuals, median follow up is 254 (range 19–4,451) and 304 (12–1,702;P= 0.03) days. Survival is 23% and 40%, respectively, favoring patients treated with CTR‐V (log rank;P= 0.03). Cox regression analysis showed that treatment group (P< 0.001), FAB type, hemoglobin level, and platelet count were independent factors for response to chemotherapy. Older age and not undergoing myeloablative therapy were the only adverse factors for survival. We conclude that increase in the treatment dose of daunorubicin in patients with AML led to a higher remission rate, particularly with a single course of chemotherapy and had an equivalent toxicity profile. This therapeutic modification is also likely to result in substantial reduction in patient stay in hospital and in the overall expenditure. Am. J. Hematol. 76:319–329, 2004.
- 1 December 2002
- Published by Wolters Kluwer Health in Transplantation
- Vol. 74 (11) , 1551-1559
Immune reconstitution at 6 months following t-cell depleted hematopoietic stem cell transplantation is predictive for treatment outcome
Compared with allogeneic bone marrow, in cytokine mobilized blood stem cell grafts, the number of hematopoietic progenitors and lymphoid cells is higher. Consequently, we compared the immune reconstitution following these two transplant modalities in patients receiving T-cell depleted grafts for hematological malignancies and studied the impact of lymphocyte subset recovery on clinical outcome. Conditioning for transplantation was radiation-based, while graft versus host disease prophylaxis was by ex vivo T-cell depletion with Campath-1 antibodies. Clinical parameters of patients receiving bone marrow or cytokine-mobilized progenitor cell transplants were reviewed with emphasis placed on defining infectious events and on the causes of treatment failure (relapse, graft failure, or any cause of death). The blood lymphoid subsets, as well as markers for memory and naive T cells, were sequentially studied by standard flow cytometry. Serum immunoglobulins (Ig) concentrations were also determined. The patient population included 15 females and 27 males with a median age of 32.5 (range 15-54) years. Source of human leukocyte antigen-identical sibling allogeneic grafts was bone marrow in 14 and peripheral blood (PBPC) in 28. The median follow-up was of 1,278 (range 47-2,466) days. Following hematopoietic recovery, within the first year, 28 patients were readmitted for pyrexial episodes, and four died of sepsis. In both groups, while the CD8+ subset recuperated rapidly, CD19 and CD4+ T cells remained significantly decreased even after 12 months, leading to persistently abnormal CD4:CD8 ratios. The median values of CD16+ and CD56+ (natural killer) cells remained normal throughout the study period. Despite the patients who were receiving PBPC grafts having significantly higher numbers of allogeneic mononuclear cells (x 10(8)/kg; median: 6.97; range 4.03-10.10 vs. 0.71; range 0.45-0.99; P<0.001) and colony-forming unit granulocyte-macrophages (CFU-GMs) (x 10(4)/kg; median: 27.75; range 0-196, 2 vs. 13.05; range 2.43-57; P<0.05), the recovery rate of B cells or T-cell subpopulations was similar to those receiving bone marrow transplantation (BMT). Double fluorescence studies showed that CD2/CD45RO and RA as well as CD4/CD45RO and RA remained subnormal even after 12 months follow-up. During the observation period, except for IgA, normal levels of immunoglobulins were detected. In all, 18 out of 42 patients failed therapy, and 14 patients died. Treatment failure occurred at a median of 270 (range 47-1,638) days and was significantly associated with low total lymphocyte count (P = 0.01), CD2 (P = 0.09), CD8 (P = 0.01), CD19 (P = 0.02), CD45RA (P = 0.05), and CD4/CD45RA (P = 0.01), when tested at 6 months from transplantation. After T-cell depleted allogeneic PBPC or BMT, no differences in the rate of immune recovery were detected. However, patients with specific subset abnormalities at 6 months from grafting had a significantly higher risk of treatment failure.
- 1 December 2002
- Published by Wolters Kluwer Health in Transplantation
- Vol. 74 (11) , 1551-1559
Immune reconstitution at 6 months following t-cell depleted hematopoietic stem cell transplantation is predictive for treatment outcome
Compared with allogeneic bone marrow, in cytokine mobilized blood stem cell grafts, the number of hematopoietic progenitors and lymphoid cells is higher. Consequently, we compared the immune reconstitution following these two transplant modalities in patients receiving T-cell depleted grafts for hematological malignancies and studied the impact of lymphocyte subset recovery on clinical outcome. Conditioning for transplantation was radiation-based, while graft versus host disease prophylaxis was by ex vivo T-cell depletion with Campath-1 antibodies. Clinical parameters of patients receiving bone marrow or cytokine-mobilized progenitor cell transplants were reviewed with emphasis placed on defining infectious events and on the causes of treatment failure (relapse, graft failure, or any cause of death). The blood lymphoid subsets, as well as markers for memory and naive T cells, were sequentially studied by standard flow cytometry. Serum immunoglobulins (Ig) concentrations were also determined. The patient population included 15 females and 27 males with a median age of 32.5 (range 15-54) years. Source of human leukocyte antigen-identical sibling allogeneic grafts was bone marrow in 14 and peripheral blood (PBPC) in 28. The median follow-up was of 1,278 (range 47-2,466) days. Following hematopoietic recovery, within the first year, 28 patients were readmitted for pyrexial episodes, and four died of sepsis. In both groups, while the CD8+ subset recuperated rapidly, CD19 and CD4+ T cells remained significantly decreased even after 12 months, leading to persistently abnormal CD4:CD8 ratios. The median values of CD16+ and CD56+ (natural killer) cells remained normal throughout the study period. Despite the patients who were receiving PBPC grafts having significantly higher numbers of allogeneic mononuclear cells (x 10(8)/kg; median: 6.97; range 4.03-10.10 vs. 0.71; range 0.45-0.99; P<0.001) and colony-forming unit granulocyte-macrophages (CFU-GMs) (x 10(4)/kg; median: 27.75; range 0-196, 2 vs. 13.05; range 2.43-57; P<0.05), the recovery rate of B cells or T-cell subpopulations was similar to those receiving bone marrow transplantation (BMT). Double fluorescence studies showed that CD2/CD45RO and RA as well as CD4/CD45RO and RA remained subnormal even after 12 months follow-up. During the observation period, except for IgA, normal levels of immunoglobulins were detected. In all, 18 out of 42 patients failed therapy, and 14 patients died. Treatment failure occurred at a median of 270 (range 47-1,638) days and was significantly associated with low total lymphocyte count (P = 0.01), CD2 (P = 0.09), CD8 (P = 0.01), CD19 (P = 0.02), CD45RA (P = 0.05), and CD4/CD45RA (P = 0.01), when tested at 6 months from transplantation. After T-cell depleted allogeneic PBPC or BMT, no differences in the rate of immune recovery were detected. However, patients with specific subset abnormalities at 6 months from grafting had a significantly higher risk of treatment failure.